Navigation Links
New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
Date:5/20/2008

WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM)(1). Patients participating in the study were ages 18 years and older with moderate to severe asthma(1) and had been previously treated with inhaled corticosteroids(1). Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008.

Results showed that patients receiving budesonide/formoterol combination therapy administered as adjustable dosage reported significantly greater satisfaction on the ATSM overall (p=0.02) than patients receiving fluticasone/salmeterol combination therapy, especially in the categories of feel medication begins to work (p<0.001), dosing management (p<0.001), and timely relief of symptoms (p=0.037)(1). Patients receiving budesonide/formoterol combination therapy fixed dose reported significantly greater satisfaction for timely relief of symptoms (p=0.002) and feeling the medication begin to work (p=0.02) compared to patients receiving fluticasone/salmeterol combination therapy(1). Budesonide/formoterol combination therapy is not indicated for adjustable dosing in the U.S.

"These data showed that patients treated with budesonide/formoterol combination therapy fixed dose were more satisfied with the timeliness of their symptom relief than those patients treated with fluticasone/salmeterol combination therapy," said lead investigator Richard O'Connor, MD, of the University of California-San Diego.

About the ATSM

Patient satisfaction was assessed using the recently validated 11-item Asthma Treatment Satisfaction Measure (ATSM)(1). Scores range from 0-100, with the higher scores equaling greater satisfaction(1). Categories included symptom relief, onset of action, sensations that medication
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
2. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
3. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
4. Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
5. Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
7. Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
8. CBI and PharmaVoice Announce Recipients of the Strategic Patient Adherence Awards
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
11. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... November 21, 2014 Two new educational webinars ... comes next for ALS research and how the pharmaceutical industry ... the Ice Bucket Challenge: Where Does the ALS Money Go? ... 2 December 2014, Time: 1:30pm ET, Register to ... speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology at ...
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)... November 22, 2014 The “Chiral ... Preparative), by Material (Metal, Glass, Plastic), by Application ... SFC] - Forecast to 2018” analyses and studies ... in North America, Europe, Asia, and Rest of ... and 15 figures spread through 135 pages and ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... BERLIN, NIMES, France and RICHMOND, Calif., June 22 ... Cezanne, and Lumiphore Inc., a biotechnology leader in ... high-value applications, announced that they have signed an ... BRAHMS diagnostic tests. , , Under ...
... solution for managing compliance and regulated content throughout the product ... SAN DIEGO, June 22 Drug Information Association ... Inc. , the market leader in enterprise content compliance ... of its Virtx integrated software suite, an end-to-end, Web-based solution ...
... , SHANGHAI, June 22 /PRNewswire-Asia/ -- ... pharmaceutical, biotechnology, and medical device,research and development outsourcing company with ... Hsu has been appointed Senior Vice,President of WuXi AppTec U.S. ... , Prior to joining WuXi, ...
Cached Biology Technology:BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 2BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 3Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 2Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 3Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 4Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 5WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations 2
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... will not become pregnant, and they cannot be helped by ... Gothenburg, Sweden, have identified a molecule called Cdk1 that has ... this could lead to an increased rate of successful IVF. ... struggle to become pregnant. In vitro fertilization (IVF) can help ...
... the University of California, Davis, have invented a superthin ... "The material itself (say, semiconductor wafers) would break ... of biomedical engineering. He and his fellow researchers have ... thick layer between two surfaces. Pan,s nanoglue, which conducts ...
... In a brief paper in the journal Bioinformatics ... Web-based program called Spliceman for predicting whether genetic mutations ... potentially leading to disease. "Spliceman takes a set ... likely these single nucleotide variants alter splicing phenotypes," write ...
Cached Biology News:Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies 2Will a genetic mutation cause trouble? Ask Spliceman 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Biology Products: